GDF15 biomarker performance in older patients with advanced non-small cell lung cancer
Lung cancer is a lethal disease responsible for the highest number of annual cancer deaths by cancer type, estimated to be 127,070 in the United States in 2023 [1]. It has a high impact on older patients with a median age of diagnosis at 71, however, this age group has not been well represented in many pivotal clinical trials. An analysis of lung cancer trials from 1990 to 2012 showed just 25.3% of patients were aged ≥70 [2]. Whilst there is increasing evidence that older people benefit from anti-cancer therapies [3], there are precious few tools to identify those most likely to tolerate and benefit from treatment.
Authors
- Rachael A. McCloy (ORCID: https://orcid.org/0000-0001-7791-4044)
- Venessa Chin (ORCID: https://orcid.org/0000-0002-4630-4451)
- Michael Boyer (ORCID: https://orcid.org/0000-0002-0452-2987)
- Anthony Joshua
- Nicholas McNamee
- Michael Krasovitsky
- Bernadette (Bea) Brown
- John Simes
Institutions
- The University of Sydney (AU)
- Garvan Institute of Medical Research (AU)
- Children's Medical Research Institute (AU)
- Westmead Hospital (AU)
- UNSW Sydney (AU)
- Chris O’Brien Lifehouse (AU)
- The Kinghorn Cancer Centre (AU)
- National Health and Medical Research Council (AU)
Publication Details
- Journal
- Journal of Geriatric Oncology
- Published
- 2026-06-09
- DOI
- https://doi.org/10.1016/j.jgo.2026.103028
- Primary Topic
- GDF15 and Related Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Health and Medical Research Council